Cue Biopharma
Natasha Girgis has worked in the biopharmaceutical industry since 2004. Natasha began their career as a Graduate Student at the Perelman School of Medicine at the University of Pennsylvania. Natasha then moved on to a Postdoctoral Fellow role at New York University in 2010. In 2015, they became a Post-doctoral Fellow in Immuno-Oncology at The Janssen Pharmaceutical Companies of Johnson & Johnson. In 2016, they were a Scientist II - Immuno Oncology at Constellation Pharmaceuticals. Most recently, they have held the roles of Associate Director, Translational Pharmacology, Principal Scientist, and Senior Scientist at Cue Biopharma since 2018.
Natasha Girgis obtained a Doctor of Philosophy (Ph.D.) in Microbiology from the University of Pennsylvania School of Medicine in 2010. Prior to that, they obtained a Bachelor's Degree in Microbiology and Immunology from the University of Rochester in 2004.
Cue Biopharma
1 followers
Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.